Sign Out
There are no adequate data from the use of FEIBA in pregnant or lactating women.
No animal reproduction studies have been conducted with FEIBA.
Physicians should balance the potential risks and only prescribe FEIBA if clearly needed, taking into consideration that pregnancy and the postpartum period confer an increased risk of thromboembolic events, and several complications of pregnancy that are associated with an increased risk of DIC.
Due to the increased risk of thrombosis during pregnancy, FEIBA should only be used under careful medical monitoring and if no alternative therapy is available.
See Warnings for information on Parvovirus B19 infection.
Continue with Google